nVerses Capital LLC bought a new position in shares of Anterix Inc. (NASDAQ:ATEX – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 1,200 shares of the company’s stock, valued at approximately $45,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in ATEX. Vanguard Group Inc. raised its position in shares of Anterix by 0.9% during the first quarter. Vanguard Group Inc. now owns 876,015 shares of the company’s stock valued at $29,443,000 after buying an additional 8,020 shares during the last quarter. Clearbridge Investments LLC lifted its stake in Anterix by 2.2% in the 1st quarter. Clearbridge Investments LLC now owns 318,021 shares of the company’s stock worth $10,689,000 after purchasing an additional 6,844 shares in the last quarter. Roubaix Capital LLC grew its position in shares of Anterix by 7.0% during the first quarter. Roubaix Capital LLC now owns 178,543 shares of the company’s stock valued at $6,001,000 after purchasing an additional 11,666 shares in the last quarter. Gabelli Funds LLC increased its holdings in shares of Anterix by 4.7% in the second quarter. Gabelli Funds LLC now owns 140,422 shares of the company’s stock worth $5,559,000 after purchasing an additional 6,322 shares during the last quarter. Finally, Gamco Investors INC. ET AL lifted its position in shares of Anterix by 24.2% in the first quarter. Gamco Investors INC. ET AL now owns 93,295 shares of the company’s stock worth $3,136,000 after buying an additional 18,195 shares in the last quarter. Institutional investors own 87.67% of the company’s stock.
Analyst Ratings Changes
A number of analysts have issued reports on the company. Craig Hallum raised Anterix to a “strong-buy” rating in a research note on Wednesday, October 9th. JPMorgan Chase & Co. increased their price objective on shares of Anterix from $60.00 to $61.00 and gave the company an “overweight” rating in a research report on Thursday, August 8th.
Anterix Stock Performance
NASDAQ ATEX opened at $31.23 on Wednesday. The business’s 50 day moving average price is $36.34 and its 200-day moving average price is $35.35. Anterix Inc. has a fifty-two week low of $28.70 and a fifty-two week high of $42.41. The company has a market cap of $580.57 million, a P/E ratio of -25.60 and a beta of 0.83.
Anterix (NASDAQ:ATEX – Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.39). Anterix had a negative net margin of 441.15% and a negative return on equity of 27.91%. The firm had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $1.64 million. During the same period in the prior year, the company posted ($0.11) EPS. As a group, equities analysts predict that Anterix Inc. will post -2.64 EPS for the current year.
About Anterix
Anterix Inc operates as a wireless communications company. The company focuses on commercializing its spectrum assets to enable the targeted utility and critical infrastructure customers to deploy private broadband networks and innovative broadband solutions. It holds licensed spectrum in the 900 MHz band with coverage throughout the United States, Alaska, Hawaii, and Puerto Rico.
Recommended Stories
- Five stocks we like better than Anterix
- Buy P&G Now, Before It Sets A New All-Time High
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- What is a Bond Market Holiday? How to Invest and Trade
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Want to see what other hedge funds are holding ATEX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anterix Inc. (NASDAQ:ATEX – Free Report).
Receive News & Ratings for Anterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anterix and related companies with MarketBeat.com's FREE daily email newsletter.